EMA 401

Drug Profile

EMA 401

Alternative Names: EMA-401

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Spinifex Pharmaceuticals
  • Developer Novartis
  • Class Analgesics; Small molecules; Tetrahydroisoquinolines
  • Mechanism of Action Angiotensin type 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuropathic pain; Postherpetic neuralgia
  • Preclinical Diabetic neuropathies

Most Recent Events

  • 04 Apr 2017 Novartis plans regulatory filings in Neuropathic pain in 2021
  • 31 Mar 2017 Novartis plans the EMPHENE phase II trial for Postherpetic neuralgia (NCT03094195)
  • 25 Aug 2015 Spinifex Pharmaceuticals withdraws prior to enrolment a phase II trial in Diabetic neuropathies in USA and the United Kingdom (NCT02435199)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top